The next webinar in the COVID-19 web series will discuss treatment of critical care and pregnant patients with COVID-19 and possible implications in pregnancy.
- Understand more about treating patients diagnosed with COVID-19
- Learn how best to manage patients in critical care
- Understand the impact of thrombosis in COVID-19 patients
- Hear the latest research on pharmacology and therapeutics
- Understand more what medication to use
- Hear the global perspective on how patients are treated in low and middle-income countries
- Ask questions to the expert panel
Watch the fifth English webinar in the COVID-19 web series
|11:00-11:05||Welcome and introduction||
Prof. Tom Bourne, Prof. Christoph Lees
|11:05-11:15||Critical Care in adults with COVID-19||Dr Nick Barrett|
|11:15-11:25||Impact of COVID-19 on pregnancy care in LMIC||Dr Hema Divakar|
|11:25-11:35||Thrombosis in COVID-19 & implications in pregnancy||Prof. Beverley Hunt|
|11:35-11:45||Pharmacology & Therapeutics in pregnancy with COVID-19||Prof. David Williams|
Executive Committee, Honours Committee, Nominations Committee
Professor Tom Bourne
ISUOG President 2020 - 2022, Virtual World Congress Technical Congress Chair 2020 and 2021, 2022 World Congress Co-Chair, Executive Committee, Finance & Risk Committee, Nominations Committee
Professor Tom Bourne was ISUOG President between 2020 and 2022 and is curently Chair in Gynaecology at Imperial College London, Hon Consultant Gynaecologist at Queen Charlottes and Chelsea hospital and Visiting Professor at KU Leuven in Belgium. He is an authority on managing early pregnancy complications, emergency gynaecology and gynaecological ultrasonography. He trained in ultrasound at Kings College Hospital in London. He subsequently worked at the University of Göteborg, Sweden as Medical Research Council visiting scientist, Hamar in Norway, and Leuven in Belgium. He was appointed senior lecturer and consultant gynaecologist at St George's University Hospital London before moving to Imperial College. He has edited seven books and published over 400 papers. He sits on the management committee of the Tommy’s National Centre for Miscarriage Research. He is medical advisor and trustee of the patient group, the Ectopic Pregnancy Trust. He is immediate Past-President of the UK Association of Early Pregnancy Units. He is co-founder and CEO of the International Ovarian Tumor Analysis (IOTA) group and sits on the steering committees of several large multicentre international trials. He is founder member of the RCOG task force on “supporting our doctors”. He is honorary fellow of the American Institute of Ultrasound in Medicine, honorary member of the Australasian Society for Ultrasound in Medicine and honorary member of the Brazilian and Hungarian Ultrasound Societies.
His principal research interest is diagnostics in early pregnancy and gynaecology including the IOTA, IETA, IDEA and MUSA studies, microbiome, metabolomics, novel biomarkers, and AI. His interests include the psychology of pregnancy loss and physician welfare including studies with the BMA and RCOG.
Specialties: Early Pregnancy Care, Emergency Gynaecology, Ultrasound in Oncology, Gynaecological Ultrasonography, Physician Wellbeing
Selected Notable Publications:
Sporadic miscarriage: evidence to provide effective care. Coomarasamy A, Gallos ID, Papadopoulou A, Dhillon-Smith RK, Al-Memar M, Brewin J, Christiansen OB, Stephenson MD, Oladapo OT, Wijeyaratne CN, Small R, Bennett PR, Regan L, Goddijn M, Devall AJ, Bourne T, Brosens JJ, Quenby S.
Lancet. 2021 May 1;397(10285):1668-1674. doi: 10.1016/S0140-6736(21)00683-8. Epub 2021 Apr 27.
Van Calster B, Valentin L, Froyman W, Landolfo C, Ceusters J, Testa AC, Wynants L, Sladkevicius P, Van Holsbeke C, Domali E, Fruscio R, Epstein E, Franchi D, Kudla MJ, Chiappa V, Alcazar JL, Leone FPG, Buonomo F, Coccia ME, Guerriero S, Deo N, Jokubkiene L, Savelli L, Fischerová D, Czekierdowski A, Kaijser J, Coosemans A, Scambia G, Vergote I, Bourne T, Timmerman D.
BMJ. 2020 Jul 30;370:m2614. doi: 10.1136/bmj.m2614.
Farren J, Jalmbrant M, Falconieri N, Mitchell-Jones N, Bobdiwala S, Al-Memar M, Tapp S, Van Calster B, Wynants L, Timmerman D, Bourne T.
Am J Obstet Gynecol. 2020 Apr; 222(4):367.e1-367.e22. doi: 10.1016/j.ajog.2019.10.102.
Froyman W, Landolfo C, De Cock B, Wynants L, Sladkevicius P, Testa AC, Van Holsbeke C, Domali E, Fruscio R, Epstein E, Dos Santos Bernardo MJ, Franchi D, Kudla MJ, Chiappa V, Alcazar JL, Leone FPG, Buonomo F, Hochberg L, Coccia ME, Guerriero S, Deo N, Jokubkiene L, Kaijser J, Coosemans A, Vergote I, Verbakel JY, Bourne T, Van Calster B, Valentin L, Timmerman D.
Lancet Oncol. 2019 Mar; 20(3): 448-458. doi: 10.1016/S1470-2045(18)30837-4.
Defining safe criteria to diagnose miscarriage: prospective observational multicentre study. Preisler J, Kopeika J, Ismail L, Vathanan V, Farren J, Abdallah Y, Battacharjee P, Van Holsbeke C, Bottomley C, Gould D, Johnson S, Stalder C, Van Calster B, Hamilton J, Timmerman D, Bourne T.
BMJ. 2015 Sep 23; 351:h4579. doi: 10.1136/bmj.h4579.
Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic studies. Van Calster B, Van Hoorde K, Valentin L, Testa AC, Fischerova D, Van Holsbeke C, Savelli L, Franchi D, Epstein E, Kaijser J, Van Belle V, Czekierdowski A, Guerriero S, Fruscio R, Lanzani C, Scala F, Bourne T, Timmerman D; International Ovarian Tumour Analysis Group.
BMJ. 2014 Oct 15;349:g5920. doi: 10.1136/bmj.g5920.
Diagnostic criteria for nonviable pregnancy early in the first trimester. Doubilet PM, Benson CB, Bourne T, Blaivas M; Society of Radiologists in Ultrasound Multispecialty Panel on Early First Trimester Diagnosis of Miscarriage and Exclusion of a Viable Intrauterine Pregnancy, Barnhart KT, Benacerraf BR, Brown DL, Filly RA, Fox JC, Goldstein SR, Kendall JL, Lyons EA, Porter MB, Pretorius DH, Timor-Tritsch IE.
N Engl J Med. 2013 Oct 10; 369(15): 1443-51. doi: 10.1056/NEJMra1302417.
Limitations of current definitions of miscarriage using mean gestational sac diameter and crown-rump length measurements: a multicenter observational study. Abdallah Y, Daemen A, Kirk E, Pexsters A, Naji O, Stalder C, Gould D, Ahmed S, Guha S, Syed S, Bottomley C, Timmerman D, Bourne T.
Ultrasound Obstet Gynecol. 2011 Nov; 38(5): 497-502. doi: 10.1002/uog.10109.
He is President of the UK Association of Early Pregnancy Units (AEPU), Trustee of the Ectopic Pregnancy Trust and on the steering committee of the International Ovarian Tumor Analysis (IOTA) trial.
Director of Guy's and St Thomas' Haemostasis Research Unit, clinical lead for haematological services at Viapath and sits on the Viapath Analytics operating board.
Perinatal Doppler and Vascular Focus Group (Chair), UOG Editorial Board
Christoph Lees is a Maternal-Fetal Medicine subspecialist, Consultant Obstetrician and Head of Fetal Medicine at Imperial College London where he is Clinical Reader. He is visiting Professor, KU Leuven, Belgium, was RCOG inaugural National Ultrasound Officer 2010-2013 and Vice Chairman, RCOG Subspecialty Committee 2011-2013. His research focuses on pre-eclampsia, cardiovascular adaptation, Doppler, intra-uterine growth restriction and non-invasive fetal surgery.
Specialties: Fetal anomaly screening T2; fetal biometry and wellbeing; aneuploidies; fetal anomalies; fetal growth restriction; maternal and fetal Doppler; preeclampsia; safety of ultrasound
Executive Committee, Nominations Committee, China Sub-Committee, UOG Editorial Board
Professor Liona Poon is an Academic Subspecialist in Maternal Fetal Medicine, devoted in improving maternal and fetal health. She has had a prolific research output throughout her clinical and research posts, including over 130 peer-reviewed publications in high impact international journals. In the last 10 years she has focused her research on establishing a programme for effective early prediction and prevention of preeclampsia, a major cause of maternal and perinatal morbidity and mortality. With her success in developing a first-trimester prediction model for preeclampsia using maternal risk factors, ultrasound, blood pressure and biochemical markers, and on Aspirin prophylaxis against preeclampsia, her goal in the next 10 years is to improve obstetric care worldwide, through clinical research and education.
Aspire trial: incidence of preterm preeclampsia in patients fulfulling ACOG and NICE criteria according to risk by the FMF algorithm. Poon LC, Rolnik DL, Tan MY, Delgado JL, Tsokaki T, Akolekar R, Singh M, Andrade W, Efeturk T, Jani JC, Plasencia W, Papaioannou G, Blazquez AR, Carbone IF, Wright D, Nikolaides KH.
Ultrasound Obstet Gynecol 2018 Jan 30. doi: 10.1002/uog.19019 [Epub ahead of print]
Aspirin versus Placebo in Pregnancies at High Risk of Preterm Preeclampsia. Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tennebaum Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides K.H.
New England Journal Medicine 2017, 2017 Jun 28. doi: 10.1056/NEJMoa1704559. [Epub ahead of print]
Country: China, Hong Kong Special Administrative Region
Specialties: Fetal anomaly screening 1st trimester and 2nd trimester; fetal biometry and wellbeing; fetal anomalies screening; aneuploidy screening; fetal anomalies; fetal growth restriction; maternal and fetal Doppler; multiple pregnancy; preeclampsia; preterm delivery; fetal growth; detection of fetal and neonatal growth abnormalities; ultrasound on the labour ward
Languages: English; Chinese (Mandarin); Chinese (Cantonese)